Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Top Cited Papers
Open Access
- 1 October 2016
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 6 (10), 1106-1117
- https://doi.org/10.1158/2159-8290.cd-16-0313
Abstract
Venetoclax monotherapy has clinical activity and is generally well tolerated in patients with heavily pretreated AML, and BCL2 dependence and lack of BCL-XL and MCL1 dependence predicted the best response.Keywords
Other Versions
Funding Information
- AbbVie Genentech (ABT-199/GDC-0199)
- Leukemia and Lymphoma Society NIH (P01 CA066996)
This publication has 42 references indexed in Scilit:
- ABT‐199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not plateletsBritish Journal of Haematology, 2013
- BH3 profiling – Measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisionsCancer Letters, 2013
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsNature Medicine, 2013
- Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cellsBlood, 2012
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid LeukemiaThe New England Journal of Medicine, 2012
- Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutationsThe Journal of Experimental Medicine, 2010
- Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia GenomeThe New England Journal of Medicine, 2009
- The Bcl-2 apoptotic switch in cancer development and therapyOncogene, 2007
- Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737JCI Insight, 2007
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003